Novo Nordisk is to begin a Phase III trial in Alzheimer’s disease of oral semaglutide, the GLP-1 analogue which is currently licensed as Rybelsus for use in patients with type 2 diabetes.
The decision is a bold one given the almost 100% failure rate seen in Alzheimer’s late-stage trials over the last...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
